Full video transcriptClick to expand
Auto-generated transcript of @elisacici_'s video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Okay, well I didn't want to say the name of the company because I'm also working at an in-person
- 0:05clinic and I didn't want to step on any toes in case a corporate got a hold.
- 0:10But I'm leaving next Friday, whatever.
- 0:13So the name of the online clinic is called ShedRX.
- 0:15I have them linked in my bio if you wanted to fill out the questionnaire and see if you
- 0:19qualified for some of the Glutide or Shr's Epitide.
- 0:22You can do that.
- 0:23It's $50 off.
- 0:24Also, if you use the link.
- 0:26But they have their some of Glutide starting at $199 per month and then Shr's Epitide starting
- 0:30at $299 per month.
- 0:32There's no membership fees.
- 0:34There's no membership fees.
- 0:36You just pay for the medication.
- 0:38You see the provider once a month and then you can all you also have the option to do health
- 0:42coaching if you want it.
- 0:43I suggested for every single person whether you are on a weight loss medication or not.
- 0:48I think everyone should see a nutritionist if you're having issues with weight or body
- 0:52at percentage or if your A1C is too high.
- 0:55But if you have any questions just send me a message, leave a comment and I will get back
- 0:59to you and good luck on your weight loss journey.
- 1:03Bye.
GLP-1 results timeline: Is 3 months the real benchmark?
Quick answer
The creator promoted compounded semaglutide and tirzepatide through ShedRx at $199 and $299 per month respectively, recommending a minimum 3-month treatment window before expecting results. Clinical trial data from SURMOUNT-1 and STEP 1 supports meaningful weight loss beginning in this window, though maximum efficacy typically accumulates over 6 to 12 months with dose titration. The video does not clarify that these are compounded formulations rather than FDA-approved branded drugs, which is a clinically relevant distinction for patients evaluating safety and consistency.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 results timeline: Is 3 months the real benchmark?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "GLP-1 results timeline: Is 3 months the real benchmark?" from Cici | CLT Nursing Student. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator promoted compounded semaglutide and tirzepatide through ShedRx at $199 and $299 per month respectively, recommending a minimum 3-month treatment window before expecting results.
The reason this review is not generic is the source wording and the canonical claim label "glp1 replying to t i f f a n y to start seeing results it s recom." In this clip, the useful excerpt is: "Okay, well I didn't want to say the name of the company because I'm also working at an in-person clinic and I didn't want to step on any toes in case a corporate got a hold." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator promoted compounded semaglutide and tirzepatide through ShedRx at $199 and $299 per month respectively, recommending a minimum 3-month treatment window before expecting results.
FormBlends verdict
Compounded Tirzepatide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator promoted compounded semaglutide and tirzepatide through ShedRx at $199 and $299 per month respectively, recommending a minimum 3-month treatment window before expecting results. Clinical trial data from SURMOUNT-1 and STEP 1 supports meaningful weight loss beginning in this window, though maximum efficacy typically accumulates over 6 to 12 months with dose titration. The video does not clarify that these are compounded formulations rather than FDA-approved branded drugs, which is a clinically relevant distinction for patients evaluating safety and consistency.
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide patients lost an average of 20.9% body weight over 72 weeks, meaning the 3-month mark is a starting point, not a finish line.
- Compounded semaglutide and tirzepatide are not FDA-approved drugs and have no established bioequivalence to Wegovy, Mounjaro, or Zepbound. The FDA has issued multiple warnings about compounded GLP-1 products.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide patients lost an average of 20.9% body weight over 72 weeks, meaning the 3-month mark is a starting point, not a finish line.
- Compounded semaglutide and tirzepatide are not FDA-approved drugs and have no established bioequivalence to Wegovy, Mounjaro, or Zepbound. The FDA has issued multiple warnings about compounded GLP-1 products.
- The FDA's legal landscape around compounded GLP-1 availability has shifted as shortage designations for semaglutide and tirzepatide have been updated, affecting compounders' legal authority to produce them.
- Nutritionist or dietitian support during GLP-1 therapy has clinical backing. STEP 5 data (Garvey et al., 2022, Nature Medicine) showed sustained lifestyle intervention improved weight maintenance outcomes.
- This video is an affiliate promotion with a disclosed $50 discount code. Creator financial relationships with platforms do not invalidate their claims, but viewers should weigh that context when evaluating recommendations.
- Monthly provider follow-up is standard for GLP-1 titration, but the quality of that follow-up matters. Asynchronous messaging is not equivalent to clinical monitoring for side effects like pancreatitis, gallbladder disease, or heart rate changes.
- If elevated A1C is a concern, tirzepatide has robust data in type 2 diabetes management from the SURPASS program, but diagnosis and treatment decisions require a licensed provider, not a telehealth intake form alone.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @elisacici_ actually say?
The creator promoted ShedRx, a telehealth platform, recommending compounded GLP-1 medications including what she called "some of Glutide" (semaglutide) starting at $199/month and "Shr's Epitide" (tirzepatide) starting at $299/month. She also stated in the caption that patients should stay on GLP-1 medication for "at least 3 months" before expecting results. She disclosed a $50 affiliate discount and recommended nutritionist support for anyone dealing with weight, body composition, or elevated A1C.
Important upfront: this is an affiliate promotion. She has a financial relationship with ShedRx. That does not automatically make her claims wrong, but it is context every viewer deserves before taking her advice at face value.
Does the science back the 3-month timeline?
The 3-month minimum is a reasonable, if somewhat conservative, benchmark. Clinical trial data on both semaglutide and tirzepatide generally shows meaningful weight loss beginning around weeks 8 to 16, with the most significant reductions accumulating over 6 to 12 months.
The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide patients losing a mean of 20.9% body weight over 72 weeks, with substantial losses still occurring well past the 3-month mark. Similarly, the STEP 1 trial (Wilding et al., 2021, NEJM) for semaglutide showed progressive weight reduction through 68 weeks. Three months will show early results for many patients, but framing it as the threshold where you "start seeing results" undersells the longer trajectory. Some patients respond faster; some need dose titration that takes several months to complete before any real efficacy window opens.
What did they get wrong, or right?
She got the nutritionist recommendation right, and it deserves credit. Behavioral and dietary support alongside GLP-1 therapy consistently improves outcomes. The STEP 5 trial extension data supports sustained lifestyle intervention as a meaningful complement to pharmacotherapy.
What she got wrong, or at least incomplete: she never clarified that the medications ShedRx dispenses are compounded versions, not FDA-approved brand-name drugs like Wegovy, Mounjaro, or Zepbound. Compounded semaglutide and tirzepatide are not equivalent to their brand-name counterparts under FDA standards. The FDA has explicitly flagged concerns about compounded GLP-1 products, including dosing inconsistencies and lack of bioequivalence data. Viewers hearing "$199 semaglutide" may not realize they are not getting Wegovy. That is a meaningful omission in a promotional video.
The pricing she quoted also reflects a market in flux. Compounded GLP-1 availability has been legally contested, and the FDA's shortage designation status for semaglutide and tirzepatide has changed over time, affecting the legal standing of compounders.
What should you actually know?
GLP-1 receptor agonists are legitimate, well-studied medications with real clinical evidence behind them. The 3-month framing in the caption is not fabricated; early clinical endpoints do show measurable changes in that window for many patients. But the more important number is 12 months, which is when the bulk of the efficacy data in pivotal trials was actually collected.
Before signing up for any compounded GLP-1 program, ask these questions directly: Is this compounded or brand-name? What is the source pharmacy, and is it an FDA-registered 503B outsourcing facility or a 503A pharmacy? What does monthly follow-up actually involve? A brief async check-in is not the same as clinical monitoring. And if your A1C is elevated, GLP-1 therapy has real metabolic benefits supported by data, including the SURPASS program for tirzepatide in type 2 diabetes management, but that is a conversation for a licensed provider, not a TikTok affiliate link.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Cici | CLT Nursing Student · TikTok creator
47.4K views on this video
Replying to @T I F F A N Y to start seeing results it’s recommended to be on GLP-1 medication for ATLEAST 3 months. #a1c #bodyfat #weightloss #tirzepatide @ShedRx #shedrx
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about surmount-1 (jastreboff et al., 2022, nejm) showed tirzepatide patients lost?
SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide patients lost an average of 20.9% body weight over 72 weeks, meaning the 3-month mark is a starting point, not a finish line.
What does the video say about compounded semaglutide?
Compounded semaglutide and tirzepatide are not FDA-approved drugs and have no established bioequivalence to Wegovy, Mounjaro, or Zepbound. The FDA has issued multiple warnings about compounded GLP-1 products.
What does the video say about the fda's legal landscape around compounded glp-1 availability has shifted?
The FDA's legal landscape around compounded GLP-1 availability has shifted as shortage designations for semaglutide and tirzepatide have been updated, affecting compounders' legal authority to produce them.
What does the video say about nutritionist?
Nutritionist or dietitian support during GLP-1 therapy has clinical backing. STEP 5 data (Garvey et al., 2022, Nature Medicine) showed sustained lifestyle intervention improved weight maintenance outcomes.
What does the video say about this video?
This video is an affiliate promotion with a disclosed $50 discount code. Creator financial relationships with platforms do not invalidate their claims, but viewers should weigh that context when evaluating recommendations.
What does the video say about monthly provider follow-up?
Monthly provider follow-up is standard for GLP-1 titration, but the quality of that follow-up matters. Asynchronous messaging is not equivalent to clinical monitoring for side effects like pancreatitis, gallbladder disease, or heart rate changes.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Cici | CLT Nursing Student, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.